Why It Matters
Aidoc Inc. is entering federal lobbying at a critical juncture for healthcare AI policy. Congress is actively debating Medicare reimbursement pathways for AI medical devices—the central issue determining whether diagnostic AI companies can achieve meaningful market adoption.
By hiring DLA Piper LLP (US), Aidoc has assembled unprecedented legislative firepower. Rachel B. Portman and Margaret Coulter Martin—both former senior health policy advisors to the Senate HELP Committee—bring direct access to the committee controlling healthcare policy.
By the Numbers
This marks Aidoc’s inaugural federal lobbying effort with a five-person team combining decades of healthcare policy experience. Karina V. Lynch brings over two decades of pharmaceutical lobbying, representing Pfizer Inc. and PhRMA on Medicare issues. Michael D. Fleischman brings AI expertise from representing OpenAI OpCo LLC and Boston Dynamics Inc..
Aidoc faces stiff competition. Viz.ai Inc. spent $400,000 lobbying in 2025, while Tempus AI Inc. spent $240,000 on similar healthcare AI initiatives.
The Agenda
Aidoc’s lobbying focuses on Health Issues (HCR) and Medicare/Medicaid (MMM) policy, targeting Medicare reimbursement pathways for FDA-cleared AI medical devices. The Health Tech Investment Act would create dedicated Medicare payment mechanisms—a direct priority for Aidoc’s commercial viability.
Additional relevant legislation includes the HEAL-AI Act, funding AI education for medical professionals, and the Right to Override Act, protecting physician authority to reject AI recommendations.
Broader Context
The regulatory environment has shifted toward deregulation under the Trump administration, dismantling transparency requirements for AI medical devices. FDA breakthrough designations for AI devices may soon qualify for automatic Medicare coverage, streamlining coverage decisions.
However, Congressional scrutiny of AI in insurance denials has created public skepticism. The FDA has approved over 1,000 AI-enabled medical devices, with radiology accounting for 75-80 percent of approvals, intensifying competition.
Between The Lines
Congress is actively reshaping AI healthcare policy as Aidoc launches its effort. The House Energy and Commerce Health Subcommittee held hearings on AI opportunities, with competitor Viz.ai participating. Rep. Mariannette Miller-Meeks (R-IA-01), a physician, has held Capitol Hill briefings on healthcare AI and secured language promoting AI-driven care in rural areas.
Bipartisan momentum is building, with physician-members like Rep. Ami Bera (D-CA-6) highlighting AI’s potential to reduce provider burnout.
Competitive Landscape
Multiple healthcare AI companies are actively lobbying. Beyond Viz.ai and Tempus AI, Tendo Systems Inc. engaged two lobbying firms to advocate on healthcare AI policy. This competitive field reflects broader congressional momentum, with multiple bills advancing that focus on reimbursement—critical for all diagnostic AI companies.
The Bottom Line
Aidoc is entering federal lobbying at a pivotal moment. While the regulatory environment favors deregulation, competitive intensity in AI radiology is accelerating. Success will depend on translating the team’s institutional access into favorable treatment within proposed bills while addressing Congressional concerns about physician autonomy and care algorithms.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article